At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 2,711 enrolled
Drug / intervention
Apixaban +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism
In Brief
A Phase 3 clinical trial evaluating Apixaban and Placebo for Venous Thrombosis. Completed, enrolled 2,711 participants across 428 sites in 29 countries.
Detailed Summary
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVenous Thrombosis
CountriesArgentina, Australia, Austria, Brazil, Canada, Chile, Czechia, Denmark, France, Germany, Hong Kong, India, Israel, Italy, Mexico, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Russia, Singapore, South Africa, South Korea, Spain, Ukraine, United Kingdom, United States
CollaboratorsPfizer
Timeline
Phase 3CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedMar 2008
Enrollment StartMay 2008
Primary CompletionAug 2012
TodayJul 2026
First PostedMar 12, 2008
Enrollment StartMay 1, 2008
Primary CompletionAug 1, 2012
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 18.3 years ago
Interventions
Apixabandrug
Tablets, Oral, twice daily, 12 months
Placebodrug
Tablets, Oral, twice daily, 12 months